ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations
Retrieved on:
Tuesday, July 5, 2022
Review, FDA, Patient, Brain, EGFR, GLOBE, Man, Disease, NSCLC, Lung cancer, Non-small-cell lung carcinoma, Mutation, Pharmacokinetics, Fast Track, HER2, Woman, Food, Therapy, Communication, Plasma protein binding, Dead on arrival, Drug development, Safety, Point mutation, Stage 2, Dose, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry
NEWTOWN SQUARE, Pa., July 05, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the first patient has been enrolled in its Phase 1b trial of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) or HER2 mutations, including exon 20 insertion mutations. Furmonertinib, an oral, irreversible, pan-EGFR mutant selective inhibitor—which has been shown to be highly brain penetrant—was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) in this indication.
Key Points:
- Furmonertinib is approved in China as an anticancer therapy for EGFR T790M NSCLC patients, and more recently, as a first-line treatment for classical EGFR mutant NSCLC patients.
- Furmonertinib is being developed in China by Allist Pharmaceuticals and in the rest of the world by ArriVent Biopharma.
- Non-small cell lung cancer (NSCLC) is the predominant subtype of lung cancer, accounting for approximately 85% of all cases.
- 31% of EGFR activating mutations are termed atypical EGFR mutations of which exon 20 insertion mutations constitute 9% of EGFR activating mutations overall.